View : 352 Download: 0
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis
- Title
- Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis
- Authors
- Salvestrini V.; Kim K.; Caini S.; Alkner S.; Ekholm M.; Skyttä T.; Becherini C.; Coles C.E.; Kaidar-Person O.; Offersen B.; de Azambuja E.; Visani L.; Cortes J.; Harbeck N.; Rugo H.S.; Isacke C.M.; Marangoni E.; Morandi A.; Lambertini M.; Poortmans P.; Livi L.; Meattini I.
- Ewha Authors
- 김규보
- SCOPUS Author ID
- 김규보
- Issue Date
- 2023
- Journal Title
- Radiotherapy and Oncology
- ISSN
- 1678-8140
- Citation
- Radiotherapy and Oncology vol. 186
- Keywords
- Breast cancer; Meta-analysis; Radiotherapy; Systematic review; T-DM1; Trastuzumab emtansine
- Publisher
- Elsevier Ireland Ltd
- Indexed
- SCIE; SCOPUS
- Document Type
- Review
- Abstract
- Background and Purpose: In recent years, the treatment landscape for breast cancer has undergone significant advancements, with the introduction of several new anticancer agents. One such agent is trastuzumab emtansine (T-DM1), an antibody drug conjugate that has shown improved outcomes in both early and advanced breast cancer. However, there is currently a lack of comprehensive evidence regarding the safety profile of combining T-DM1 with radiation therapy (RT). In this study, we aim to provide a summary of the available data on the safety of combining RT with T-DM1 in both early and metastatic breast cancer settings. Materials and Methods: This systematic review and meta-analysis project is part of the consensus recommendations by the European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee on integrating RT with targeted treatments for breast cancer. A thorough literature search was conducted using the PUBMED/MedLine, Embase, and Cochrane databases to identify original studies focusing on the safety profile of combining T-DM1 with RT. Results: After applying eligibility criteria, nine articles were included in the meta-analysis. Pooled data from these studies revealed a high incidence of grade 3 + radionecrosis (17%), while the rates of grade 3 + radiation-related pneumonitis (<1%) and skin toxicity (1%) were found to be very low. Conclusion: Although there is some concern regarding a slight increase in pneumonitis when combining T-DM1 with postoperative RT, the safety profile of this combination was deemed acceptable for locoregional treatment in non-metastatic breast cancer. However, caution is advised when irradiating intracranial sites concurrently with T-DM1. There is a pressing need for international consensus guidelines regarding the safety considerations of combining T-DM1 and RT for breast cancer. © 2023 The Author(s)
- DOI
- 10.1016/j.radonc.2023.109805
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML